Evidence & regulatory context
- Mechanism
- Recombinant elastin-like protein hydrogel nerve-conduit filler; biomaterial construct, not in ChEMBL.
- Target
- Not recorded
- Injury models
- Other
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatOtherSprague-DawleyMixed sex, with sex-matched experimental groupsn = 25 rats in total, 12 in the ELP group and 13 in the empty c…Surgical implantation into the lumen of a nerve guidance conduit at the injury site3% weight per volume final ELP concentration, RGD concentra…At the time of injury, in the same operation as the transection
Model: Acute complete sciatic nerve transection approximately 2 mm above the trifurcation with a 5 mm segment removed to create a 10 mm gap, bridged by a 14 mm silicone conduit (inner diameter 1.98 mm) sutured with 9-0 nylon
ELP-filled conduits produced tissue bridges in all animals and a significantly higher sciatic functional index at 6 weeks than empty conduits, but compound muscle action potential amplitude, conduction velocity and muscle atrophy did not differ significantly between groups.
Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.